Insider Trading Alert - ENS, HOS And PCRX Traded By Insiders
at The Street - Tue May 13, 10:45AM CDT
Stocks with insider trader activity include ENS, HOS and PCRX
Use Options For A Chance To Buy PCRX At A 25% Discount
at The Street - Fri May 09, 10:44AM CDT
Looking back to 31 days ago, Pacira Pharmaceuticals priced a 1,600,000 share secondary stock offering at $64.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the...
Insider Trading Alert - BLL, PCRX And TIBX Traded By Insiders
at The Street - Thu May 08, 11:07AM CDT
Stocks with insider trader activity include BLL, PCRX and TIBX
Pacira Pharmaceuticals, Inc. Announces sNDA Submission for EXPAREL Nerve Block Indication
Business Wire - Wed May 07, 5:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a nerve block indication for EXPAREL(R) (bupivacaine liposome injectable suspension). The sNDA is based on positive data from a Phase 3 study assessing the safety and efficacy of EXPAREL in femoral nerve block for total knee arthroplasty, and will also include additional safety data from a Phase 3 study of EXPAREL used to perform an intercostal nerve block for thoracotomy.
Wider-than-Expected Loss at Pacira, Revs Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:30AM CDT
Shares of Pacira Pharma (PCRX) have been rising since the company reported first quarter results
Released and Scheduled Earnings Results - Analyst Notes on Pacira, Exact Sciences, Synageva, Agios and Vanda Pharmaceuticals
PR Newswire - Tue May 06, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Exact Sciences Corporation (NASDAQ: EXAS), Synageva BioPharma Corp. (NASDAQ: GEVA), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2054-100free.
'Fast Money' Recap: Financial Sector Follies
at The Street - Tue May 06, 4:00AM CDT
The trading panel discussed which stocks have done well and which have not.
Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Business Wire - Mon May 05, 2:30PM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014, at 8 a.m. PT in Las Vegas. Mr. Stack is expected to present an overview of the company.
Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue of $34.4 Million and First Quarter 2014 Results
Business Wire - Thu May 01, 5:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the commercial success of EXPAREL(R) (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2014.
Frost & Sullivan Research Reveals Clinical and Economic Advantages of ON-Q* over Bupivacaine Liposome Injectable Suspension
PR Newswire - Wed Apr 30, 8:00AM CDT
I-Flow LLC, a Kimberly-Clark Health Care Company and manufacturer of the ON-Q Pain Relief System (ON-Q), today announced the full findings of a Frost & Sullivan white paper documenting clinician perspective that ON-Q delivers superior pain control over the full length of the postoperative period and at a lower cost compared to Bupivacaine Liposome Injectable Suspension.
Pacira Pharmaceuticals (PCRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:57AM CDT
Pacira Pharmaceuticals is actually looking pretty good on its own too. The firms prospects looks good in both the short and long term.
Early Briefing on Pharma Equities -- Research on TherapeuticsMD, Pacira Pharma, GW Pharma, and Depomed
PR Newswire - Mon Apr 21, 10:00AM CDT
The trading session on Thursday, April 17, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,408.54, down 0.10% and the NASDAQ Composite closed at 4,095.52, up 0.23%. The S&P 500 finished the session 0.14% higher at 1,864.85. During the trading session, seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day flat at 658.58, while it has edged lower by 0.30% in previous three months. Investor-Edge has initiated coverage on the following equities: TherapeuticsMD Inc. (NYSE MKT: TXMD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), GW Pharmaceuticals PLC (NASDAQ: GWPH) and Depomed Inc. (NASDAQ: DEPO). Free technical research on TXMD, PCRX, GWPH and DEPO can be downloaded upon signing up at:
Pacira Pharmaceuticals Announces Timing for First Quarter 2014 Financial Results Webcast and Conference Call
Business Wire - Thu Apr 17, 5:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial results for the company's first quarter ended March 31, 2014, will be released before the market opens on Thursday, May 1, 2014. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Thursday, May 1, 2014, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) fifteen minutes prior to the start of the call and providing the Conference ID 2786177.
Global Meningioma Clinical Trials Review 2014
M2 - Wed Apr 16, 10:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xnw5zr/meningioma_global) has announced the addition of the "Meningioma Global Clinical Trials Review, H1, 2014" report to their offering. Meningioma Global Clinical Trials Review, H1, 2014 provides data on the Meningioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Meningioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Meningioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies - Novartis AG - Pacira Pharmaceuticals, Inc. - Mundipharma International Limited - China Nuokang Bio-Pharmaceutical Inc. - Burzynski Research Institute, Inc. - Arno Therapeutics, Inc. Organisations - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Northwestern University - Memorial Sloan Kettering Cancer Center - The University of Utah - Abramson Cancer Center - European Organization for Research and Treatment of Cancer - Southwest Oncology Group - City of Hope National Medical Center - New York University School of Medicine For more information visit http://www.researchandmarkets.com/research/xn...oma_global
Pacira Pharmaceuticals Announces Grants of Inducement Stock Options Under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Tue Apr 15, 3:40PM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that on April 15, 2014, it approved the grant of stock options to 17 new employees to purchase an aggregate of 81,000 shares of common stock. The stock options were granted as inducements material to the new employees entering into employment with Pacira, as permitted under NASDAQ Listing Rule 5635(c)(4).
Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free
Pacira Prices Offering, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 11:00AM CDT
Shares of Pacira Pharmaceuticals soared 11.3% on the news of the pricing of the common stock at an offer price of $64.00 per share.
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:21AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) was a big mover last session, as the company saw its shares rise by over 11% on the day.
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 09, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: